Skip to main content

Table 5 Responder status for primary PRO measures from baseline to long-term follow-up visits

From: Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Primary PRO measure Time point from baseline of the ATLAS study
  Week 36 Week 52 Week 76 Week 104 Week 128 Week 156
SF-36 PCS responder, ≥ 3-point decrease from baseline
   n b 265 263 255 229 227
   Responders, n (%) b 201 (75.8)a 197 (74.9)a 204 (80.0)a 182 (79.5)a 186 (81.9)a
BASFI responder, ≥ 21% reduction from baseline
   n 278 274 270 261 242 236
   Responders, n (%) 203 (73.0)a 208 (75.9)a 211 (78.1)a 210 (80.5)a 195 (80.6)a 193 (81.8)a
ASQOL responder, ≥ 1.8-point reduction from baseline
   n b 274 270 263 242 236
   Responders, n (%) b 211 (77.0)a 212 (78.5)a 213 (81.0)a 193 (79.8)a 188 (79.7)a
  1. aP < 0.001; chi-square test for equal proportions was performed.
  2. bMeasure not assessed at this time point.
  3. ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASFI = Bath AS Functional Index; PCS = Physical Component Summary; PRO = patient-reported outcome; SF-36 = Short Form-36 Health Survey.